Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Clinical Trials
20 clinical trials for Pathologic Stage IIID Cutaneous Melanoma AJCC v8 across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer — RECRUITING · PHASE1
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer — RECRUITING · PHASE1
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
- Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement — TERMINATED · PHASE2
- A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers — ACTIVE_NOT_RECRUITING · PHASE1
- Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors — ACTIVE_NOT_RECRUITING
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — ACTIVE_NOT_RECRUITING · PHASE2
- Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 — ACTIVE_NOT_RECRUITING · PHASE1
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
- Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma — COMPLETED · PHASE2
- Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies — TERMINATED · PHASE1
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
- Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors — ACTIVE_NOT_RECRUITING
- Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients — ACTIVE_NOT_RECRUITING · PHASE1
- Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma — TERMINATED · PHASE1
- Bone Loss in Melanoma Survivors Receiving Immunotherapy — TERMINATED
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies — TERMINATED · PHASE1
- Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma — TERMINATED · PHASE2
- Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma — TERMINATED · PHASE2
Refine this search